A comparision between of Donepezil vs. Donepezil and Trazodonee efficacy in the cognitive impairment among elderly Patients with Dementia

A comparision between of Donepezil vs. Donepezil and Trazodonee efficacy in the cognitive impairment among elderly Patients with Dementia: A Randomized, Double-Blind Trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190317043079N1

Enrollment

Registered

2019-10-04

Start date

2019-04-04

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive impairment. Mild cognitive impairment, so stated

Interventions

Intervention 1: Intervention group1: Donepezil (Jalinous Company) in dosage of 5 mg during 1 month then induction of drug dosage to 10 mg for 2 months. Intervention 2: Intervention group2: Donepezil

Eligibility

Sex/Gender

All

Age

65 Years to 95 Years

Inclusion criteria

Inclusion criteria: Elderly patients with dementia

Exclusion criteria

Exclusion criteria: History of diabetes, blood pressure, thyroid problem, and reversible dementia

Design outcomes

Primary

Measure	Time frame
Severity of cognitive impairment. Timepoint: Before starting treatment and six months after starting treatment. Method of measurement: mini mental status exam(MMSE) questionnaire.	—

Secondary

Measure	Time frame
Sevirity of Cognitive impairment. Timepoint: Before starting treatment and six months after starting treatment. Method of measurement: Addenbrooke's cognitive examination questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Farzan Kheirkhah

Babol University of Medical Sciences

drfarzankh@yahoo.com+98 11 3229 1951

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026